Literature DB >> 24315293

Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%.

Audrey Chia1, Wei-Han Chua1, Li Wen2, Allan Fong1, Yar Yen Goon3, Donald Tan4.   

Abstract

PURPOSE: To study the change in spherical equivalent and other ocular parameters 1 year after stopping the administration of atropine.
DESIGN: Prospective randomized double-masked clinical trial.
METHODS: We assigned 400 myopic children, 6 to 12 years of age, to receive atropine 0.5%, 0.1% or 0.01% for 24 months, after which medication was stopped. Parents and children gave informed consent to participate in the research. Children were reviewed at 26, 32 and 36 months, and changes in cycloplegic spherical equivalent (SE), axial length (AL), visual acuity, pupil size, and accommodation were assessed.
RESULTS: Of the children, 356 (89%) entered into the washout phase. At entry, there was no significant difference in age, gender, SE, or AL among the children in the various atropine groups. Over the following 12 months, myopic progression was greater in the 0.5% eyes (-0.87 ± 0.52 D), compared to the 0.1% (-0.68 ± 0.45 D) and 0.01% eyes (-0.28 ± 0.33 D, P < 0.001). AL growth was also greater in the 0.5% (0.35 ± 0.20 mm) and 0.1% (0.33 ± 0.18 mm) eyes, compared to the 0.01% eyes (0.19 ± 0.13 mm, P < 0.001). Pupil size and near visual acuity returned to pre-atropine levels in all groups, but accommodation at 36 months was less in the 0.5% eyes (13.24 ± 2.72 D) compared to the 0.1% (14.45 ± 2.61 D) and 0.01% eyes (14.04 ± 2.90 D, P < 0.001). The overall increase in SE over the entire 36 months in the 0.5%, 0.1% and 0.01% groups was -1.15 ± 0.81 D, -1.04 ± 0.83 D and -0.72 ± 0.72 D, respectively (P < 0.001).
CONCLUSION: There was a myopic rebound after atropine was stopped, and it was greater in eyes that had received 0.5% and 0.1% atropine. The 0.01% atropine effect, however, was more modulated and sustained.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24315293     DOI: 10.1016/j.ajo.2013.09.020

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  69 in total

Review 1.  Understanding and Treating Myopia: What More We Need to Know and Future Research Priorities.

Authors:  Sally A McFadden
Journal:  Optom Vis Sci       Date:  2016-09       Impact factor: 1.973

2.  Bifocal & Atropine in Myopia Study: Baseline Data and Methods.

Authors:  Juan Huang; Donald O Mutti; Lisa A Jones-Jordan; Jeffrey J Walline
Journal:  Optom Vis Sci       Date:  2019-05       Impact factor: 1.973

Review 3.  Efficacy and Adverse Effects of Atropine in Childhood Myopia: A Meta-analysis.

Authors:  Qianwen Gong; Miroslaw Janowski; Mi Luo; Hong Wei; Bingjie Chen; Guoyuan Yang; Longqian Liu
Journal:  JAMA Ophthalmol       Date:  2017-06-01       Impact factor: 7.389

4.  Preventing Myopia.

Authors:  Wolf A Lagrèze; Frank Schaeffel
Journal:  Dtsch Arztebl Int       Date:  2017-09-04       Impact factor: 5.594

5.  Additive effects of orthokeratology and atropine 0.01% ophthalmic solution in slowing axial elongation in children with myopia: first year results.

Authors:  Nozomi Kinoshita; Yasuhiro Konno; Naoki Hamada; Yoshinobu Kanda; Machiko Shimmura-Tomita; Akihiro Kakehashi
Journal:  Jpn J Ophthalmol       Date:  2018-07-04       Impact factor: 2.447

Review 6.  [Biological mechanisms of myopia].

Authors:  F Schaeffel
Journal:  Ophthalmologe       Date:  2017-01       Impact factor: 1.059

7.  Childhood myopia: epidemiology, risk factors, and prevention.

Authors:  Matthew Recko; Erin Durrie Stahl
Journal:  Mo Med       Date:  2015 Mar-Apr

8.  Current trends among pediatric ophthalmologists to decrease myopia progression-an international perspective.

Authors:  Ofira Zloto; Tamara Wygnanski-Jaffe; Sonal K Farzavandi; Rosario Gomez-de-Liaño; Derek T Sprunger; Eedy Mezer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-08-03       Impact factor: 3.117

9.  Opposing effects of atropine and timolol on the color and luminance emmetropization mechanisms in chicks.

Authors:  Laura A Goldberg; Frances J Rucker
Journal:  Vision Res       Date:  2016-03-19       Impact factor: 1.886

Review 10.  Pharmacogenomic Approach to Antimyopia Drug Development: Pathways Lead the Way.

Authors:  Tatiana V Tkatchenko; Andrei V Tkatchenko
Journal:  Trends Pharmacol Sci       Date:  2019-10-30       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.